Drug updated on 9/12/2023

Dosage FormInjection (subcutaneous; 25 mg/0.5 mL, 50 mg/mL)
Drug ClassTumor necrosis factor (TNF) blocker
Ongoing and Completed StudiesClinicalTrials.gov


  • For the treatment of rheumatoid arthritis (RA).
  • For the treatment of polyarticular juvenile idiopathic arthritis (JIA) in patients aged 2 years or older.
  • For the treatment of Psoriatic Arthritis (PsA).
  • For the treatment of ankylosing spondylitis (AS).
  • For the treatment of plaque psoriasis (PsO) in patients 4 years or older.

Product Monograph / Prescribing Information

Document TitleYearSource
Enbrel (etanercept) Prescribing Information.2022Immunex Corporation, Thousand Oaks, CA

Systematic Reviews / Meta-Analyses

Clinical Practice Guidelines